MTOR and Cognitive impairment: The combination of these elements supported the running of the study Cognition, Age, and RaPamycin Effectiveness–DownregulatIon of the mTOR-pathway (CARPE DIEM), an early phase 1 clinical trial, involving 10 patients, in a single group, finalized to evaluate the effect of oral Rapamycin in older adults with AD and mild cognitive impairment (MCI).